News
HLTRF
3.540
NaN%
--
HLS Therapeutics GAAP EPS of -$0.12, revenue of $13.5M
Seeking Alpha · 11/13 15:13
Stocks in play: HLS Therapeutics Inc.
Barchart · 10/30 08:51
Weekly Report: what happened at HLTRF last week (0908-0912)?
Weekly Report · 09/15 09:56
Weekly Report: what happened at HLTRF last week (0901-0905)?
Weekly Report · 09/08 09:57
Weekly Report: what happened at HLTRF last week (0825-0829)?
Weekly Report · 09/01 09:55
Weekly Report: what happened at HLTRF last week (0818-0822)?
Weekly Report · 08/25 09:59
Weekly Report: what happened at HLTRF last week (0811-0815)?
Weekly Report · 08/18 09:56
HLS Therapeutics reports mixed Q2 results; reaffirms FY25 outlook
Seeking Alpha · 08/14 12:39
Weekly Report: what happened at HLTRF last week (0804-0808)?
Weekly Report · 08/11 09:59
Weekly Report: what happened at HLTRF last week (0728-0801)?
Weekly Report · 08/04 10:00
Stocks in play: HLS Therapeutics Inc.
Barchart · 07/31 09:08
Weekly Report: what happened at HLTRF last week (0721-0725)?
Weekly Report · 07/28 10:01
Weekly Report: what happened at HLTRF last week (0714-0718)?
Weekly Report · 07/21 09:56
Weekly Report: what happened at HLTRF last week (0707-0711)?
Weekly Report · 07/14 10:00
Weekly Report: what happened at HLTRF last week (0630-0704)?
Weekly Report · 07/07 09:57
Weekly Report: what happened at HLTRF last week (0623-0627)?
Weekly Report · 06/30 09:59
Weekly Report: what happened at HLTRF last week (0616-0620)?
Weekly Report · 06/23 09:57
Weekly Report: what happened at HLTRF last week (0609-0613)?
Weekly Report · 06/16 09:59
Weekly Report: what happened at HLTRF last week (0602-0606)?
Weekly Report · 06/09 09:59
Weekly Report: what happened at HLTRF last week (0526-0530)?
Weekly Report · 06/02 10:03
More
Webull provides a variety of real-time HLTRF stock news. You can receive the latest news about Hls Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About HLTRF
HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.